106 results
Page 3 of 6
8-K
EX-99.2
jw9z0t3 1p1
6 May 22
Ocugen Provides Business Update and First Quarter 2022 Financial Results
6:44am
8-K
EX-99.1
nms23zm56e9gc9g7r
20 Apr 22
Other Events
5:11pm
8-K
EX-99.1
xuxznxg8csj 6reqctv
12 Apr 22
Other Events
9:07am
8-K
EX-99.1
uuvl8yufv
4 Apr 22
Other Events
5:01pm
8-K
EX-99.1
d35hw4
11 Mar 22
Other Events
4:24pm
424B5
9sty6xixsq8xmn
24 Feb 22
Prospectus supplement for primary offering
5:00pm
424B5
6fip81ejp33
22 Feb 22
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.1
8x1 q1kio6l0c
22 Feb 22
Other Events
7:36am
8-K
EX-99.1
p7o5 jsz2
12 Jan 22
Other Events
4:05pm
8-K
EX-99.1
uflsv5j4spbvsz7k0j
10 Jan 22
Other Events
4:07pm
8-K
EX-99.1
m5wp5e2xikxsqws
30 Dec 21
Other Events
4:27pm
8-K
EX-99.1
318u6n9xqu4gu 0ipud
26 Nov 21
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating
7:38am
8-K
EX-99.1
ntats
8 Nov 21
Ocugen, Inc. Announces Submission of Investigational New Drug Application
9:25am
8-K
EX-99.1
4vo nsxuky8
27 Oct 21
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
8:10am
424B7
76zuqyjg
6 Aug 21
Prospectus with selling stockholder info
4:05pm
8-K
EX-99.1
78vq4uzu4npp
6 Jul 21
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
6:02am